| Literature DB >> 15642114 |
Justyna Jólkowska1, Anna Pieczonka, Tomasz Strabel, Dariusz Boruczkowski, Jacek Wachowiak, Peter Bader, Michal Witt.
Abstract
BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is performed mainly in patients with high-risk or advanced hematologic malignancies and congenital or acquired aplastic anemias. In the context of the significant risk of graft failure after allo-HSCT from alternative donors and the risk of relapse in recipients transplanted for malignancy, the precise monitoring of posttransplant hematopoietic chimerism is of utmost interest. Useful molecular methods for chimerism quantification after allogeneic transplantation, aimed at distinguishing precisely between donor's and recipient's cells, are PCR-based analyses of polymorphic DNA markers. Such analyses can be performed regardless of donor's and recipient's sex. Additionally, in patients after sex-mismatched allo-HSCT, fluorescent in situ hybridization (FISH) can be applied.Entities:
Year: 2005 PMID: 15642114 PMCID: PMC546008 DOI: 10.1186/1471-2326-5-1
Source DB: PubMed Journal: BMC Blood Disord ISSN: 1471-2326
Comparison of results using different DNA sizing technologies and FISH
| 1. | 67 | F | AML | PB | 04.09.1998 | 542 | 100% | 100% | 100% |
| 556 | 100% | 100% | 100% | ||||||
| 574 | 100% | 100% | 100% | ||||||
| 590 | 100% | 100% | 100% | ||||||
| 639 | 100% | 100% | 100% | ||||||
| 675 | 100% | 100% | 100% | ||||||
| 697 | 100% | 100% | 100% | ||||||
| 721 | 100% | 100% | 100% | ||||||
| 750 | 100% | 100% | 100% | ||||||
| 2. | 102 | M | AML | PB | 12.10.2000 | 14 | 84% | 86% | 89% |
| 19 | 49% | 47% | 51% | ||||||
| 28 | 40% | 40% | 35% | ||||||
| 35 | 47% | 42% | 12% | ||||||
| 57 | 46% | 35% | 6% | ||||||
| 3. | 106 | M | FA | PB | 21.12.2000 | 7 | 100% | 100% | 92% |
| 48 | 26% | 27% | 32% | ||||||
| 91 | 13% | 14% | 9% | ||||||
| 4. | 87 | F | FA | PB | 27.12.1999 | 21 | 10% | 28% | ND |
| 38 | 93% | 94% | ND | ||||||
| 285 | 15% | 18% | ND | ||||||
| 313 | 17% | 19% | ND | ||||||
| 357 | 0% | 0% | ND | ||||||
| 5. | 45 | F | CML | PB | 15.11.1996 | 953 | 0% | 0% | ND |
| 1030 | 0% | 0% | ND | ||||||
| 1216 | 0% | 0% | ND | ||||||
| 1284 | 0% | 0% | 0% | ||||||
| 1374 | 0% | 0% | 0% | ||||||
| 1459 | 0% | 0% | 0% | ||||||
| 1492 | 0% | 0% | ND | ||||||
| 6. | 93 | F | AML | PB | 20.04.2000 | 28 | 0% | 0% | 0% |
| 158 | 0% | 0% | 0% | ||||||
| 277 | 0% | 0% | 0% | ||||||
| 7. | 109 | F | MDS | PB | 26.01.2001 | 14 | 0% | 0% | 0% |
| 21 | 0% | 0% | ND | ||||||
| 34 | 0% | 0% | ND | ||||||
| 42 | 0% | 0% | ND | ||||||
| 8. | 108 | F | ALL | PB | 19.01.2001 | 17 | 0% | 0% | ND |
| 21 | 0% | 0% | ND | ||||||
| 26 | 0% | 0% | 2% | ||||||
| 39 | 0% | 0% | ND | ||||||
| 52 | 0% | 0% | ND | ||||||
| 60 | 0% | 0% | ND | ||||||
| 9. | 88 | F | AML | PB | 21.01.2000 | 29 | 0% | 0% | ND |
| 87 | 0% | 0% | 0% | ||||||
| 178 | 0% | 0% | ND | ||||||
| 267 | 0% | 0% | ND | ||||||
| 365 | 0% | 0% | 2% | ||||||
| 10. | 95 | F | ALL | PB | 16.06.2000 | 27 | 0% | 0% | ND |
| 83 | 0% | 0% | ND | ||||||
| 200 | 0% | 0% | ND | ||||||
| 218 | 0% | 0% | 1% |
ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; CML = chronic myelogenous leukemia; FA = Fanconi Anemia; FISH = fluorescent in situ hybridization; HSCT = hematopoietic stem cell transplantation; MDS = myelodysplastic syndrome; ND = no data; PB = peripheral blood; UPN = unique patient's number
* results expressed as % of recipient's cells
Coefficients of Spearman rank correlation between results of chimerism quantification by different methods (all coefficients significant, P < 0.001).
| PCR/ALF Express | 0.987 | 0.801 |
| PCR/ABI 310 Genetic Analyzer | 0.825 |